论文部分内容阅读
目的观察补元通络汤治疗糖尿病肾病(DN)Ⅲ期的临床疗效。方法 74例DNⅢ期患者随机分治疗组和对照组各37例,在基础治疗的同时对照组口服厄贝沙坦片每天150mg,治疗组在对照组基础上给予补元通络汤口服,每日1剂,两组均以28天为1个疗程,共观察6个疗程。比较治疗前后两组患者尿微量白蛋白与尿肌酐比值(UACR)、24h尿蛋白定量、肾小球率过滤(GFR)、血肌酐(Cr)及中医证候评分,治疗后判定疾病疗效及中医证候疗效。结果治疗后两组患者UACR、24h尿蛋白定量、血Cr、中医证候积分较治疗前明显降低,GFR明显升高(P<0.05);治疗后治疗组UACR、24h蛋白尿定量及中医证候积分较对照组降低明显(P<0.05)。治疗组疾病疗效和中医证候疗效总有效率均为87.10%,对照组分别为64.86%、59.46%,治疗组疾病疗效及中医证候疗效均优于对照组(P<0.05)。结论补元通络汤联合厄贝沙坦治疗DNⅢ期患者疗效肯定,并且在改善中医证候及蛋白尿方面优于单纯西药治疗。
Objective To observe the clinical effect of BuYuanTongluo Decoction on diabetic nephropathy (DN) stage Ⅲ. Methods A total of 74 patients with DN stage Ⅲ were randomly divided into treatment group (n = 37) and control group (n = 37). At the same time, the control group received irbesartan 150 mg daily. The treatment group was given BuYuTuoLuo decoction daily, 1 dose, both groups are 28 days for a course of treatment, a total of 6 courses of observation. The urinary albumin to urinary creatinine ratio (UACR), 24h urinary protein, glomerular filtration rate (GFR), serum creatinine (Cr) and TCM syndrome score were compared between the two groups before and after treatment to determine the curative effect of the disease and Chinese medicine Syndrome efficacy. Results After treatment, UACR, 24h urinary protein, blood Cr, TCM syndrome scores were significantly lower than before treatment and GFR was significantly increased (P <0.05); After treatment, UACR, 24h proteinuria and TCM syndromes The score was significantly lower than that of the control group (P <0.05). The curative effect of the treatment group and the total effective rate of the traditional Chinese medicine syndrome were 87.10% and 64.86%, 59.46% respectively in the control group. The curative effect of the treatment group and the effect of TCM syndrome were better than the control group (P <0.05). Conclusion BuYuan Tongluo Decoction combined with irbesartan treatment of patients with DN Ⅲ affirmative effect, and in improving TCM syndromes and proteinuria is superior to Western medicine alone.